Epithelial Transfer of the Tyrosine Kinase Inhibitors Erlotinib, Gefitinib, Afatinib, Crizotinib, Sorafenib, Sunitinib, and Dasatinib: Implications for Clinical Resistance

SIMPLE SUMMARY: Tyrosine kinase inhibitors (TKIs) specifically inhibit phosphorylation of signaling pathways of cancer cells, thereby inhibiting their growth. They are characterized by a poor solubility and high protein binding, leading to a large variability in gut uptake after oral administration...

Descripción completa

Detalles Bibliográficos
Autores principales: Honeywell, Richard J., Kathmann, Ietje, Giovannetti, Elisa, Tibaldi, Carmelo, Smit, Egbert F., Rovithi, Maria N., Verheul, Henk M.W., Peters, Godefridus J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7696666/
https://www.ncbi.nlm.nih.gov/pubmed/33182766
http://dx.doi.org/10.3390/cancers12113322

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7696666/
https://www.ncbi.nlm.nih.gov/pubmed/33182766
http://dx.doi.org/10.3390/cancers12113322

Ejemplares similares